Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
(2022) Future Oncology — Vol. 18, n° 1, p. 35-45 (2022)
Files
Details
- Authors
Sartor, Oliver 
George, Daniel Agarwal, Neeraj Shore, Neal
- Abstract
- (en) AIM: To evaluate real-world clinical outcomes of radium-223 or alternative novel hormonal therapy (NHT) following first-line NHT for metastatic castration-resistant prostate cancer (mCRPC). PATIENTS & METHODS: Retrospective analysis of the US Flatiron database (ClinicalTrials.gov identifier: NCT03896984). RESULTS: In the radium-223 cohort (n = 120) versus the alternative NHT cohort (n = 226), proportionally more patients had prior symptomatic skeletal events and bone-only metastases, and first-line NHT duration was shorter. Following second-line therapy, 49 versus 39% of patients received subsequent life-prolonging therapy; of these, 47 versus 76% received taxane. Median overall survival was 10.8 versus 11.2 months. CONCLUSION: Real-world patients with mCRPC had similar median overall survival following second-line radium-223 or alternative NHT after first-line NHT. Many patients received subsequent therapy, with less taxane use after radium-223.
- Affiliations
Citations
Sartor, O., George, D., Tombal, B., Agarwal, N., Higano, C. S., Sternberg, C. N., Miller, K., Jiao, X., Guo, H., Sandström, P., Bruno, A., Verholen, F., Saad, F., & Shore, N. (2022). Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncology, 18(1), 35-45. https://doi.org/10.2217/fon-2021-0886 (Original work published 2022)